A single drop of blood on a dark surface

One Blood Test for 50 Cancers Just Cleared an FDA Panel. Here's What It Can — and Can't — Tell You

DobroMedOnline

Sep 30

5 min read

Imagine a single blood draw that could flag pancreatic, ovarian, or liver cancer — cancers that today are usually found only after they cause symptoms, often too late.

That test exists. It's called Galleri, and on September 23 an FDA advisory panel voted that its benefits outweigh its risks. Headlines called it a breakthrough. Some doctors on the panel called it something closer to a coin toss for early cancers.

Both sides are looking at the same data. Here's what it actually says.

What happened this week

Galleri is made by GRAIL. It looks for tiny fragments of tumor DNA floating in the blood and reads chemical "tags" on that DNA (methylation patterns) that are typical of cancer. If it finds a cancer signal, it also predicts where in the body the signal is probably coming from.

On September 23, 2026, the FDA's Molecular and Clinical Genetics Devices Panel voted on Galleri for adults 50 and older:

Safety: 10–0 in favor
Effectiveness: 6–4 in favor
Benefits outweigh risks: 7–2, with one abstention

The FDA isn't bound by the panel, but it often follows its advice. A final decision is expected in the coming months. If approved, Galleri would be the first FDA-approved test that screens for many cancers at once.

A day earlier, Nature Medicine published PATHFINDER 2, the largest U.S. study of the test.

One thing surprises most people: you can already buy Galleri today. It has been sold for years as a lab-developed test, with a prescription, at a list price of $949. What's pending is FDA approval — not availability.

A single pale grain standing out among hundreds of dark ones

What the best evidence shows

PATHFINDER 2 (Nature Medicine, September 2026)

About 35,900 adults aged 50 and older with no suspicion of cancer had the test and were followed for a year. Among the 32,007 people in the main analysis:

287 people (about 0.9%) got a "cancer signal detected" result.
173 of them turned out to have cancer. That's a positive predictive value of 60% — roughly 6 out of 10 positive results were real.
When a signal was real, the test pointed to the right organ 91% of the time.
About half of the cancers it found were stage I or II.
Specificity was 99.6%: very few people without cancer got a positive result.
Researchers had to screen 185 people to find one cancer.

Now the part the headlines skipped. Of all the cancers diagnosed in the group within a year, the test caught only 39%. For a prespecified group of 12 deadly cancers, it caught 70%. It was weakest for the cancers we already screen well for, like breast and prostate.

NHS-Galleri (England, results presented in May 2026)

This is the study that matters most, because it's the only randomized trial. About 142,000 people aged 50–77 were split into two groups: usual care, or usual care plus a yearly Galleri test for three years.

The main goal was missed. The trial aimed to show fewer cancers diagnosed at stage III or IV combined. It didn't. The numbers were essentially the same in both groups.
Stage IV diagnoses did fall: 14% fewer overall, and 22% and 26% fewer in the second and third years. That was a secondary goal, and the full results haven't yet been published in a peer-reviewed journal.
The test group had four times as many cancers found by screening, and 25% fewer cancers first discovered in the emergency room.

What no study has shown yet is the thing everyone actually wants to know: do people who take this test live longer? Fewer stage IV diagnoses is encouraging. It is not the same as fewer deaths.

A woman in her fifties reading a test result at her kitchen table

What's being missed in the headlines

"No cancer signal detected" does not mean "no cancer." This was the panel's biggest worry. The test misses most early cancers — one critic at the hearing noted it missed more than 85% of stage I cancers. A panel member said even some doctors who wrote in to support the test seemed to believe it could rule cancer out. It can't. The danger is false reassurance: someone skips a colonoscopy or ignores a new symptom because the blood test came back clean.

A positive result starts a process, not a diagnosis. About 4 in 10 positives are false alarms. A positive result means imaging, often a CT or PET scan, sometimes a biopsy. The $949 doesn't cover any of that. In PATHFINDER 2, 0.6% of all participants had an invasive procedure after a positive test. Most were not surgery, and no serious test-related harms were reported, but the anxiety and bills are real.

It's an add-on, not a replacement. Even GRAIL says Galleri should be used on top of standard screening. The tests we already have — colonoscopy or stool tests, mammograms, cervical screening, and lung CT for heavy smokers — have decades of evidence, and several of them are proven to prevent deaths.

Insurance mostly won't pay. Medicare doesn't cover Galleri now. A law signed in February 2026 allows Medicare to start covering FDA-approved multi-cancer tests in 2028, with age limits and only if CMS decides coverage is appropriate. Most private insurers don't cover it. Some Medicare Advantage plans, employers, and TRICARE programs do.

An empty waiting-room chair with a coat left over the back

Who might reasonably consider it

There's no guideline recommending multi-cancer blood tests for routine screening yet. It's a personal decision, and it's reasonable to talk it through if you:

are 50 or older, and
are already up to date on your recommended screenings, and
have higher risk — for example, a long smoking history or a strong family history of cancer — and
are comfortable paying out of pocket, and with the possibility of follow-up scans after a false alarm.

It's probably not the right tool if you'd use it instead of a colonoscopy or mammogram, if the cost would strain your budget, or if an uncertain result would cause you serious distress.

GRAIL doesn't recommend the test during pregnancy, for anyone 21 or younger, or during active cancer treatment.

When a blood test is the wrong tool

If you have symptoms, you don't need a screening test — you need an evaluation. See a clinician promptly for:

unexplained weight loss
blood in stool, urine, or when you cough
a new lump anywhere
difficulty swallowing that doesn't go away
persistent new pain, a cough that won't quit, or night sweats
bleeding after menopause

A "clean" Galleri result is not a reason to wait on any of these.

A woman in her sixties looking directly at the camera

The practical takeaway

The screening tests that save the most lives are the ones you're probably overdue for. Before paying for a new test, check the basics:

Colorectal cancer: ages 45–75, stool test or colonoscopy
Breast cancer: mammogram every 2 years, ages 40–74
Cervical cancer: ages 21–65, Pap and/or HPV test
Lung cancer: yearly low-dose CT, ages 50–80, for people with a 20 pack-year smoking history who smoke now or quit within 15 years
Prostate cancer: ages 55–69, a PSA decision to make together with your clinician

Galleri may one day become part of that list. Right now it's a promising, expensive, imperfect extra: good at finding some cancers nothing else screens for, and not good enough to tell you you're in the clear.

If you're not sure which screenings you're due for, or you want help deciding whether a test like Galleri makes sense for you, a DobroMed Online visit is a good place to sort it out.